These results suggested that tumor antigen presentation and a certain degree of T cell priming had already occurred in lymph nodes at baseline prior to the anti-PD-L1 mAb treatment in the FM3A model but that PD-L1 on antigen-presenting cells suppressed T cell priming, and the anti-PD-L1 mAb unleashed the T cells (see hypothesized mechanism of action in Fig. 5G, left). Here, CD274 is linked to neoplasm.